North American view on the European Sentinel Registry of the Transcatheter Valve Implantation pilot study

EuroIntervention 2013;8:1353-1355. DOI: 10.4244/EIJV8I12A206

Jeffrey Popma
Jeffrey J. Popma1, MD; Michael J. Reardon2*, MD
1. Beth Israel Deaconess Medical Center Boston, MA, USA; 2. Department of Cardiothoracic Surgery, The Methodist Debakey Heart and Vascular Center, Houston, TX, USA
Transcatheter aortic valve implantation (TAVI) is a technology introduced to care for a population of patients with symptomatic severe aortic stenosis who were either not receiving care or receiving aortic valve replacement albeit at a high risk. Although this technology potentially provided life-saving treatment, it was both expensive and itself came at substantial risk. Europe has been a leader in TAVI and recently the United States and Canada have joined with completion of the randomised Placement of Aortic Transcatheter Valves (PARTNER) Trials in non-operative and high-risk patients for surgical aortic valve replacement1,2. These studies, coupled with prospectively enrolled European national ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Building bridges for tomorrow: the EAPCI and YOUNG Interventionalists

Latest news